- Current report filing (8-K)
November 17 2010 - 4:17PM
Edgar (US Regulatory)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
:
November 16
, 2010
AVI
BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer
|
incorporation)
|
|
|
|
Identification No.)
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices, including zip code)
(425) 354-5038
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
|
Attached
hereto as Exhibit 3.1 are amendments to Sections 3.6, 3.9(c) and 4.3(d) of
the bylaws of AVI BioPharma, Inc. (the Company) adopted by the board of
directors (the Board) on November 16, 2010.
The
amendment to Section 3.6 reduces the notice period for special meetings of
the Board from five (5) days to forty-eight (48) hours and provides for
notice via facsimile or electronic mail.
Sections
3.9(c) and 4.3(d) previously provided for action by unanimous written
consent in lieu of meeting for the Board and committees thereof. The amendments to these sections permit
action by unanimous consent of the Board or committees thereof via electronic
transmission.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit Number
|
|
Description
|
3.1
|
|
Amendments
to the bylaws of the Company, effective November 16, 2010.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
AVI BioPharma, Inc.
|
|
|
|
By:
|
/s/
J. David Boyle II
|
|
|
J. David Boyle II
|
|
|
Interim President and Chief Executive
Officer, and Senior Vice President and Chief Financial Officer
|
Date:
November 17, 2010
3
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
3.1
|
|
Amendments
to the bylaws of the Company, effective November 16, 2010.
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024